Volume 6, Issue 2 (8-2004)                   yafte 2004, 6(2): 9-19 | Back to browse issues page

XML Persian Abstract Print

Abstract:   (19551 Views)
Introduction: Helicobacter pylori infection is associated with a wide range of digestive diseases and is very prevalent in developing countries, although few data exist on the susceptibility of helicobacter pylori to antimicrobial agents. The aim of this study was to determine the susceptibility patterns in helicobacter pylori strains isolated from patients in Kermanshah to twelve antimicrobial agents. Material and Methods: 72 helicobacter pylori strains isolated from gastric biopsies of patients refered to Imam khomini Hospital in Kermanshah. MIC and susceptibility of these strains to Amoxicillin, Ciprofloxacin, Clarithromycin, Erythromycin, Furazolidone, Gentamicin, Nalidixic acid, Nitrofurantoin, Metronidazole, Penicillin, Rifampin and Tetracycline was determined by using agar dilution method. Results: Resistance rates were Amoxicilin 14%, Ciprofloxacin 42%, Clarithromycin 8%, Erythromycin 21%, Furazolodone 26%, Gentamicin 35%, Nalidoxin acid 26%, Nitrofurantion 34%, Metronidazole 29%, Penicilin 26% and Rifampin 36% respectively. Cut off concentration for resistance and MICs are on full text. Conclusion: The percentage of resistant strains in Kermanshah was similar to that observed in developing countries. The results indicate that an antibiotic should not be used as the only agents in treatment of helicobacter pylori infection. The prevalence of resistance in helicobacter pylori was high in regard to Ciprofloxacin, Metronidazole, Nalidixic acid and Tetracycline (34%-42%) whereas. For Furazolidone, Gentamicin, Nitrofurantoin, Penicillin and Rifampin were moderate (21%-29%) and, for Clarithromycin and Erythromycin were low (8%-10%).
Full-Text [DOC 162 kb]   (3376 Downloads)    
Type of Study: Research |
Received: 2012/12/22 | Accepted: 2021/10/13 | Published: 2004/08/15

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.